



Docket No.: PF-00492 DIV

TECH CENTER 1600/2900

JUN 22 2001

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on June 13, 2001

By:

Emma F. Durrell

Printed:

Emma F. Durrell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Coleman et al.

Title: A NOVEL HUMAN JAK2 KINASE

Serial No.: 09/467,100

Filing Date: December 10, 1999

Examiner: Hutson, R.

Group Art Unit: 1652

Commissioner for Patents
Box Non-fee Amendment
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office Action dated March 13, 2001 (Office Action), Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

IN THE SPECIFICATION

Please replace the paragraph beginning at page 4, line 28, with the following rewritten paragraph:

Antisense molecules, antibodies, antagonists or inhibitors (including proteins, peptides, oligopeptides or organic molecules capable of compromising or modulating HJAK2 expression) may also be used for therapeutic purposes, for example, in neutralizing the aberrant activity of a HJAK2 associated with, for example, inflammation or oncogenesis. The present invention also provides for pharmaceutical compositions for the treatment of disease states associated with aberrant expression of hjak2 comprising the aforementioned antisense molecules, antibodies, antagonists or inhibitors.